A trastuzumab-PROTAC conjugate (Ab-PROTAC 3) was shown to induce catalytic protein degradation only in HER2 positive breast cancer cell lines, while sparing HER2-negative cells [105]. This evidence concerns the gene ERBB2 and breast cancer.